Selective Tumor Cell Killing by Triptolide in P53 Wild-type and P53 Mutant Ovarian Carcinomas

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2014 Jun 2

PMID 24880464

Citations 9

Authors

Jianyuan Wu

Qingdi Quentin Li

Huiping Zhou

YinYing Lu

Jueli M Li

Yao Ma

Li Wang

TingTing Fu

Xingjiang Gong

Michael Weintraub

Shuangchan Wu

Hong Ding

Affiliations

Soon will be listed here.

Abstract

Triptolide is a traditional Chinese medicinal herb-derived antineoplastic agent. However, its antitumor activity against gynecologic carcinomas has not yet been well described. It is the purpose of this article to investigate the effect and mechanism of triptolide in human ovarian cancer using both A2780 (p53 wild) and OVCAR-3 (p53 mutated) cells. Our results showed that triptolide exerted a potent inhibitory effect on the growth and proliferation of both cell lines in a dose- and time-dependent manner and that the effect was independent of the expression of p53. In contrast, triptolide had only a marginal cytotoxicity in noncancerous ovary cells, lung fibroblast cells, and macrophage cells, indicating differential inhibitory effects of the drug on cell growth between ovarian cancer cells and normal tissue cells. Exposure of the ovarian cancer cells to triptolide induced apoptosis, as evaluated by annexin V/propidium iodide-labeled flow cytometry. Triptolide-induced apoptosis was accompanied by cytochrome c release and caspase-3 activation and was associated with downregulation of Bcl-2 and upregulation of Bax. Cell cycle analysis demonstrated that treatment with triptolide induced cell cycle S phase arrest in A2780 cells and G2/M phase arrest in OVCAR-3 cells. Further detection by Western blotting revealed that the cell cycle arrest by triptolide in both cell lines occurred in concert with increased expression of p21(CIP1/WAF1). This study shows that triptolide selectively kills ovarian cancer cells with different p53 status predominantly through regulating the coordinate and dynamic cellular processes of proliferation and apoptosis, thereby making it a promising chemotherapeutic agent against a broad spectrum of ovarian carcinomas.

Citing Articles

Dapagliflozin alleviates renal podocyte pyroptosis via regulation of the HO‑1/NLRP3 axis.

Zhang Z, Ni P, Tang M, Song Y, Liu C, Zhao B Mol Med Rep. 2023; 28(5).

PMID: 37711056 PMC: 10539996. DOI: 10.3892/mmr.2023.13087.

Mechanisms and Advances in Anti-Ovarian Cancer with Natural Plants Component.

Wu J, Zhou T, Wang Y, Jiang Y, Wang Y Molecules. 2021; 26(19).

PMID: 34641493 PMC: 8512305. DOI: 10.3390/molecules26195949.

Discovery of potential targets of Triptolide through inverse docking in ovarian cancer cells.

Wu Q, Bao G, Pan Y, Qian X, Gao F PeerJ. 2020; 8:e8620.

PMID: 32219016 PMC: 7085293. DOI: 10.7717/peerj.8620.

The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer SKOV3 Cells.

Liu H, Shen M, Zhao D, Ru D, Duan Y, Ding C Biomed Res Int. 2019; 2019:2595801.

PMID: 31240207 PMC: 6556367. DOI: 10.1155/2019/2595801.

Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner.

Zhang F, Ho D, Wong R Oncotarget. 2018; 9(32):22301-22315.

PMID: 29854279 PMC: 5976465. DOI: 10.18632/oncotarget.24737.

References

Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao D . Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29(2):218-24. DOI: 10.1097/01.pas.0000146025.91953.8d. View

OConnor P, Jackman J, Bae I, Myers T, Fan S, Mutoh M . Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997; 57(19):4285-300. View

Lee K, Park J, Jee Y, Rosen G . Triptolide sensitizes lung cancer cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by inhibition of NF-kappaB activation. Exp Mol Med. 2003; 34(6):462-8. DOI: 10.1038/emm.2002.64. View

Yang S, Chen J, Guo Z, Xu X, Wang L, Pei X . Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003; 2(1):65-72. View

Doreswamy K, Shrilatha B, Rajeshkumar T, Muralidhara . Nickel-induced oxidative stress in testis of mice: evidence of DNA damage and genotoxic effects. J Androl. 2004; 25(6):996-1003. DOI: 10.1002/j.1939-4640.2004.tb03173.x. View

Zhou J, Liu M, Luthra R, Jones J, Aneja R, Chandra R . EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol. 2005; 55(5):461-5. DOI: 10.1007/s00280-004-0903-1. View

Chang W, Kang J, Lee K, Wei K, Anderson E, Gotmare S . Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem. 2000; 276(3):2221-7. DOI: 10.1074/jbc.M009713200. View

Thaker P, Deavers M, Celestino J, Thornton A, Fletcher M, Landen C . EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004; 10(15):5145-50. DOI: 10.1158/1078-0432.CCR-03-0589. View

Wang Z, Jin H, Xu R, Mei Q, Fan D . Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med. 2009; 41(10):717-27. PMC: 2772974. DOI: 10.3858/emm.2009.41.10.078. View

10.

Pan J . RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett. 2010; 292(2):149-52. DOI: 10.1016/j.canlet.2009.11.018. View

11.

Li L, Luan Y, Li X, Tang B, Zhang W, Li D . Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis. Oncol Rep. 2005; 13(5):793-9. View

12.

Fidler J, Li K, Chung C, Wei K, Ross J, Gao M . PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol Cancer Ther. 2003; 2(9):855-62. View

13.

Tengchaisri T, Chawengkirttikul R, Rachaphaew N, Reutrakul V, Sangsuwan R, Sirisinha S . Antitumor activity of triptolide against cholangiocarcinoma growth in vitro and in hamsters. Cancer Lett. 1999; 133(2):169-75. DOI: 10.1016/s0304-3835(98)00222-5. View

14.

Bouton L, Ramirez C, Bailey D, Yeatman C, Yue J, Wright H . Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion. Exp Hematol. 2004; 32(12):1137-45. DOI: 10.1016/j.exphem.2004.09.002. View

15.

Wang X, Witting P, Salvatore B, Neuzil J . Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochem Biophys Res Commun. 2004; 326(2):282-9. DOI: 10.1016/j.bbrc.2004.11.028. View

16.

Wan C, Wang C, Cheung H, Yang M, Fong W . Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett. 2005; 241(1):31-41. DOI: 10.1016/j.canlet.2005.10.001. View

17.

Abramova N, Cassarino D, Khan S, Painter T, Bennett Jr J . Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res. 2002; 67(4):494-500. DOI: 10.1002/jnr.10127. View

18.

Zhao F, Chen Y, Li R, Liu Y, Wen L, Zhang C . Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology. 2009; 267(1-3):70-9. DOI: 10.1016/j.tox.2009.10.023. View

19.

Kim R . Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005; 103(8):1551-60. DOI: 10.1002/cncr.20947. View

20.

Panichakul T, Wanun T, Reutrakul V, Sirisinha S . Synergistic cytotoxicity and apoptosis induced in human cholangiocarcinoma cell lines by a combined treatment with tumor necrosis factor-alpha (TNF-alpha) and triptolide. Asian Pac J Allergy Immunol. 2003; 20(3):167-73. View